Viracta Therapeutics
(OTC) VIRX
Viracta Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$738.00K
Net Income (TTM)
$43.29M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
VIRX News
VIRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Viracta Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
26
CEO
Mark A. Rothera, MBA
Website
www.viracta.comHeadquarters
Cardiff-by-the-Sea, CA 92007, US
VIRX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-1%
Return on Capital
-3%
Return on Assets
-90%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$492.00K
Operating Income
$50.69M
EBITDA
$46.86M
Operating Cash Flow
$39.89M
Capital Expenditure
$138.00K
Free Cash Flow
$40.03M
Cash & ST Invst.
$53.69M
Total Debt
$25.56M
Viracta Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
+100.0%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
26
N/A
Net Income
$10.55M
+16.2%
EBITDA
$9.76M
+15.2%
Quarterly Fundamentals
Net Cash
$4.22M
-88.7%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
+100.0%
Long Term Debt
$0.00
N/A
Short Term Debt
$16.91M
-34.8%
Return on Assets
-90.06%
N/A
Return on Invested Capital
-2.77%
N/A
Free Cash Flow
$7.09M
+32.3%
Operating Cash Flow
$7.09M
+32.7%